
Poseida Therapeutics (PSTX) Stock Forecast & Price Target
Poseida Therapeutics (PSTX) Analyst Ratings
Bulls say
Poseida Therapeutics Inc. has demonstrated significant advancements in its cell therapy portfolio, highlighted by promising results from its P-BCMA-ALLO1 clinical trial, where a heavily pretreated patient achieved a complete response after treatment. The company is enhancing its in-house manufacturing capabilities and exploring innovative technologies such as AI-assisted donor screening and improved gene editing efficiency, which could lead to higher product yields and overall therapeutic effectiveness. Additionally, the potential partnership with Roche is poised to leverage their extensive R&D and commercialization expertise, thereby maximizing the clinical and commercial prospects of Poseida's pipeline.
Bears say
Poseida Therapeutics has faced a downgrade in its rating due to a reassessment of its financial outlook, with a significant reduction in the 12-month price target from $20 to $9. This adjustment reflects concerns regarding the company’s progress and viability in advancing its CAR-T pipeline, especially in the context of clinical results such as the dose-dependent depletion of primary human B cells observed in preclinical models. Overall, these developments raise questions about Poseida's competitive positioning and potential for commercialization in a challenging biopharmaceutical landscape.
This aggregate rating is based on analysts' research of Poseida Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Poseida Therapeutics (PSTX) Analyst Forecast & Price Prediction
Start investing in Poseida Therapeutics (PSTX)
Order type
Buy in
Order amount
Est. shares
0 shares